Conventional G-banding cytogenetics (CC) detects chromosome 17 (chr17) abnormalities in 2% of patients with de novo myelodysplastic syndromes (MDS). We used CC and fluorescence in situ hybridization (FISH) (LSI p53/17p13.1) to assess deletion of 17p in 531 patients with de novo MDS from the Spanish Group of Hematological Cytogenetics. FISH detected -17 or 17p abnormalities in 13 cases (2.6%) in whom no 17p abnormalities were revealed by CC: 9% of patients with a normal karyotype, 0% in non-informative cytogenetics, 50% of patients with a chr17 abnormality without loss of 17p and in 4.7% of cases with an abnormal karyotype not involving chr17. Our results suggest that applying FISH of 17p13 to identify the number of copies of the TP53 gene could be beneficial in patients with a complex karyotype. We recommend using FISH of 17p13 in young patients with a normal karyotype or non-informative cytogenetics, and always in isolated del(17p)
Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders, characterized by inefficient hematopoiesis, peripheral blood cytopenias, and an increased risk of progression to acute myeloid leukemia (AML) [1] [2] [3] . Both the prognosis and the clinical course of MDS are highly variable, and several scoring systems have been developed to assess prognosis [4] [5] [6] [7] .
Chromosomal abnormalities in bone marrow cells are found in 40-60% of MDS patients [8] , while, using conventional G-banding cytogenetics(CC), alterations of chromosome 17 (chr17) are detected in 2% of patients with de novo MDS [9] . The most common abnormalities detected by CC are deletion of [(del)]5q, monosomy 7, del(7q), gain of chromosome 8 [add (8) ], del(11q), del(12p), isochromosome 17q(i17q), and del(20q) [10] .
Detection of cytogenetic abnormalities is integral to the prognostic evaluation of patients with MDS. The International Prognostic Scoring System (IPSS), which categorizes cytogenetic abnormalities as low risk, intermediate risk, or high risk, has become the gold standard for risk assessment in de novo MDS [4] . Chromosome (chr) 17 abnormalities are included in the intermediaterisk group if they are not present in a complex karyotype. The revised IPSS(R-IPSS) classification for cytogenetic abnormalities [11] involves five groups proposed by Schanz et al [12] , and includes i(17q) as a single anomaly in the intermediate cytogenetic risk group.
Recently, our group published a cooperative study that compared the prognostic impact of chr17 abnormalities (n=88) with that of other karyotypic abnormalities (n=1070) in patients with primary MDS [9] . In agreement with the R-IPSS classification, this study confirmed the intermediate prognostic impact
ofi(17q) [11, 12] .It also demonstrated that different types of chr17 abnormalities confer different prognoses: patients with monosomy 17 (-17) as part of a complex karyotype were found to havethe poorest prognosis. Interestingly, it also demonstrated that chr17 abnormalities are more commonly associated with complex karyotypes than are non-chr17 abnormalities. Consequently, patients with chr17 abnormalities are often associated with higher-risk MDS, and therefore could potentially benefit from active therapies -for example, regimens [13] [14] [15] . Thus, detection of any chr17 abnormalitiesat diagnosis is important, as it enables more accurate prediction of the patient's prognosis and the selection of appropriate treatment options.
Although CC is the gold standard technique for clinical karyotyping, it is associated with some limitations: cells must be divided from the neoplastic clone,and the sensitivity of the technique is relatively low. Fluorescence in situ hybridization (FISH) is a commonlyused technique that identifies specific abnormalities, does not require cell division, and can be easily quantified.Previous studies demonstrated the value of FISH in detectingchr5
and 7 abnormalities in patients with MDS [16, 17] .The main advantage of FISH versus CC is the higher sensitivity, with respect to the number of cells analyzed (CC analyzes only 20 metaphases). However, FISH only provides information relating to the specific region to which the probe hybridizes; it yields no information about other chromosomes.
The objective of the present study was to apply FISH of 17p to a large cohort of patients withde novo MDS,in whom CC had failed to detect del(17p).
Materials and methods

Patients
Patients from hospitals belonging to the Grupo Cooperativo Español de Citogenética Hematológica (GCECGH; Spanish Group of Hematological Cytogenetics) were divided into two groups according to their cytogenetic profile (Group A or B depending onwhetherornot they showedlossofthe short armof chr17).
Group A (n = 501) included patients in whom CC had failed to detect the following specific chr17 abnormalities: i(17q), -17, del(17p), or add(17p or del(17p). The number of interphase nuclei analyzed ranged from 100 to 400.
Interphase FISH cut-off percentages varied between centers. The median cutoff values for -17and del(17p) were 10% and 5%, respectively.
Theory
In patients with MDS, chromosomal abnormalities have been found in up to 40-60% of cases [8] . By CC, alterations of chr17 are detected in 2% of patients with de novo MDS [9] . CC has become the gold standard for karyotyping, but has limitations. FISH, for which cell division is not required, is a highly sensitive technique that enables examination of a large number of cells.
Patients with de novo MDS and chr17 abnormalities typically have a poor prognosis and poor outcomes [9] . Thus, it is important to detect chr17 abnormalities at the time of diagnosis of MDS patients, in order to ensure that the most appropriate treatment options are selected.
We hypothesized that FISH of TP53 could potentially identify del(17p) in some MDS patients in whom CC had failed to detect this abnormality.
To date, few studies have been published that describe the benefits of applying 17p FISH at the time of diagnosis of patients with de novo MDS. Those studies that have been published did not exclusively analyze del(17p) in patients with MDS.To our knowledge, the present study included the largest cohort of patients with de novo MDS in whom FISH has been applied to detect del(17p).
Results
In total, 531 patients with de novo MDS from 18 hospitals belonging to the GCECGH were included in the study. Tables 1A and 1B show the diagnosis of these patients according to FAB and/or WHO 2008 criteria. Using CC, 501
patients were found to have no i(17q), -17, del(17p), or add(17p) abnormalities (Group A), while 30 patients had abnormalities of these types (Group B). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Table A1 ).
Discussion
To date, few studies have been published that demonstrate the benefits of applying FISH of TP53 during the diagnosis of patients with de novo MDS. To our knowledge, our study cohort is the largest de novo MDS population that has been analyzed by FISH of 17p or TP53. Overall, 2.6% of patients in our study were found by FISH to have chr17 abnormalities that were not detected by CC. In the majority of these cases, CC had indicated abnormal karyotypes. Of the 220 patients with a normal karyotype Few published studies have assessed the use of FISH specifically to detect chr17 aberrations during the diagnosis of patients with de novo MDS (Table 4 ). However, several small studies have highlighted the importance of chr17 abnormalities in the pathogenesis of the disease. In a study of patients with MDS (n=11) or AML (n=6) and chr17 abnormalities [15 with unbalanced translocations, one with -17, and one with i(17q)], FISH identified TP53 deletion in 14 of the 16 patients (88%) to whom the technique was applied [21] . All but one of these patients had p53 mutations and/or overexpression. Similarly, in a study of 43 patients with del(5q) MDS (n=26)/AML (n=17), FISH confirmed chr17 abnormalities in 10 patients (23%), all of whom had complex karyotypes [22] . Moreover, TP53 mutations were detected in 17% and 53% of patients with isolated del(5q) or complex karyotype, respectively, and were found to be associated with shorter survival. These findings suggest that TP53 plays a pathogenic role in a proportion of patients with MDS, and that FISH analysis would be valuable to identify such individuals.
In addition to being of value in identifying chr17 abnormalities in elderly patients with MDS, FISH may be an important tool in the assessment of cases of pediatric MDS. Although pediatric MDS is relatively rare, accounting for less than 10% of childhood hematologic diseases [23] , where it does occur it is often found TP53 mutations and chr17 abnormalities in 7.5% and 24.2% of patients, respectively [25] . Furthermore, TP53 mutations were associated with the occurrence of del(17p) (p<0.001). The authors also observed that TP53 mutations were associated with markers of poor prognosis, such as complex karyotypes, thrombocytopenia, and a high proportion of bone marrow blasts, and were found mainly in patients with intermediate-2-/high-risk IPSS cytogenetics (79%). After adjusting for IPSS risk group, TP53 mutations were associated with shorter survival, and can therefore be considered an independent predictor of survival.
In the present study, -17 or 17p abnormalities were detected only by FISH, and not by CC, in 13 patients (2.6%). In patients with CC-detected chr17 abnormalities that did not involve loss of 17p (subgroup A17), FISH detected del(17p) in 50% of cases. In these patients, FISH enabled the patients' prognosis to be better defined, by determining the type of chr17 aberration present [9] .
FISH detected del(17p) in 4.7% of patients who, according to CC, had an abnormal karyotypewithout chr17 abnormalities. By CC, these patients presented an abnormal karyotype without evidence of loss of TP53 (no deletions in the short arm of chr17);by FISH, however, loss of TP53 was detected. In patients in whom CC detected an abnormal karyotype and -17, FISH failed to confirm -17 or loss of TP53. In view of its association with a poor prognosis in patients with a complex karyotype [9] , detection of -17 is of particular importance. Thus, FISH of 17p could be of great benefit in these 
Conclusions
The prognostic impact of chr17 abnormalities in patients with primary MDS is well established. Thus, the identification of the TP53 deletion does impact on outcome because adding FISH for the detection of TP53 deletion to CC enables more accurate prediction of the patient's prognosis and the selection of appropriate treatment options. The research leading to this invention has received funding from "la Caixa"
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ofi(17q) [11, 12] .It also demonstrated that different types of chr17 abnormalities confer different prognoses: patients with monosomy 17 (-17) as part of a complex karyotype were found to havethe poorest prognosis. Interestingly, it also demonstrated that chr17 abnormalities are more commonly associated with complex karyotypes than are non-chr17 abnormalities. Consequently, patients with chr17 abnormalities are often associated with higher-risk MDS, and therefore could potentially benefit from active therapies -for example, The objective of the present study was to apply FISH of 17p to a large cohort of patients withde novo MDS,in whom CC had failed to detect del(17p).
Materials and methods
Patients
Group A (n = 501) included patients in whom CC had failed to detect the following specific chr17 abnormalities: i(17q), -17, del(17p), or add(17p). Group 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Trias i Pujol, Badalona. All patients provided written informed consent.
CC and FISH analysis of TP53
Prior to treatment, CC and FISH were performed on bone marrow samples Interphase FISH cut-off percentages varied between centers. The median cutoff values for -17and del(17p) were 10% and 5%, respectively.
Theory
In patients with MDS, chromosomal abnormalities have been found in up to 40-60% of cases [8] . By CC, alterations of chr17 are detected in 2% of patients with de novo MDS [9] . CC has become the gold standard for Patients with de novo MDS and chr17 abnormalities typically have a poor prognosis and poor outcomes [9] . Thus, it is important to detect chr17 abnormalities at the time of diagnosis of MDS patients, in order to ensure that the most appropriate treatment options are selected.
To date, few studies have been published that describe the benefits of 
Results
In total, 531 patients with de novo MDS from 18 hospitals belonging to the GCECGH were included in the study. Tables 1A and 1B In patients classified by CC as having an abnormal karyotype not involving chr17 (subgroup AOUT17), FISH detected del(17p) in 4.7% of cases. Table 3 shows the characteristics of those patients in our study with del(17p) that was detected by FISH alone.. Table A1 ).
FISH revealed deletion of
Discussion
To date, few studies have been published that demonstrate the benefits of applying FISH of TP53 during the diagnosis of patients with de novo MDS. To our knowledge, our study cohort is the largest de novo MDS population that has been analyzed by FISH of 17p or TP53. Table 4 summarizes the main previously published studies in which FISH wasused to detect del(17p)in patients with MDS. It should be noted that none of these studiesanalyzeddel(17p) exclusively.
Overall, 2.6% of patients in our study were found by FISH to have chr17 abnormalities that were not detected by CC. In the majority of these cases, CC to have a del(5q) abnormality when analyzed by CC [16] . Similarly, Adema et al.
reported that, when FISH of 7q31 was performed in 773 MDS patients in whom CC failed to detect any chr7 abnormalities, just over 5% of the patients did indeed have chr7 abnormalities [17] . In both of the above studies, the authors recommended that FISH analysis should be mandatory in specific circumstances for patients in whom CC has detected no abnormalities, or for whom insufficient metaphases are available. Our own previous data suggest that FISH is also valuable in some cases to verify the presence of specific karyotypic abnormalities detected by CC. In a study carried out on behalf of the [21] . All but one of these patients had p53 mutations and/or overexpression. Similarly, in a study of 43 patients with del(5q) MDS (n=26)/AML (n=17), FISH confirmed chr17 abnormalities in 10 patients (23%), all of whom had complex karyotypes [22] . Moreover, TP53 mutations were detected in 17% and 53% of patients with isolated del(5q) or complex karyotype, respectively, and were found to be associated with shorter survival. These findings suggest that TP53 plays a pathogenic role in a proportion of patients with MDS, and that FISH analysis would be valuable to identify such individuals.
In addition to being of value in identifying chr17 abnormalities in elderly patients with MDS, FISH may be an important tool in the assessment of cases of pediatric MDS. Although pediatric MDS is relatively rare, accounting for less found TP53 mutations and chr17 abnormalities in 7.5% and 24.2% of patients, respectively [25] . Furthermore, TP53 mutations were associated with the occurrence of del(17p) (p<0.001). The authors also observed that TP53 mutations were associated with markers of poor prognosis, such as complex karyotypes, thrombocytopenia, and a high proportion of bone marrow blasts, and were found mainly in patients with intermediate-2-/high-risk IPSS cytogenetics (79%). After adjusting for IPSS risk group, TP53 mutations were associated with shorter survival, and can therefore be considered an independent predictor of survival.
Conclusions
The prognostic impact of chr17 abnormalities in patients with primary MDS is well established. Thus, the identification of the TP53 deletion does impact on outcome because adding FISH for the detection of TP53 deletion to CC enables more accurate prediction of the patient's prognosis and the selection of appropriate treatment options.
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